Ver Donck K - Search Results

1

Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

Ver Donck K. Ver Donck K. Pharm World Sci. 1994 Apr 15;16(2):69-76. doi: 10.1007/BF01880658. Pharm World Sci. 1994. PMID: 8032344 Review.

2

Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence.

Ver Donck KL, Verheyen WJ, Van Belle H. Ver Donck KL, et al. J Mol Cell Cardiol. 1991 Jul;23(7):783-5. doi: 10.1016/0022-2828(91)90211-4. J Mol Cell Cardiol. 1991. PMID: 1791629

3

Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine.

Snoeck E, Ver Donck K, Jacqmin P, Van Belle H, Dupont AG, Van Peer A, Danhof M. Snoeck E, et al. Among authors: ver donck k. J Pharmacol Exp Ther. 1998 Jul;286(1):142-9. J Pharmacol Exp Ther. 1998. PMID: 9655853

4

Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates.

Snoeck E, Piotrovskij V, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Woestenborghs R, Van Belle H, Van Bortel L, Van Gool R, Dupont AG, Heykants J. Snoeck E, et al. Among authors: ver donck k. Br J Clin Pharmacol. 1997 Jun;43(6):603-12. doi: 10.1046/j.1365-2125.1997.00593.x. Br J Clin Pharmacol. 1997. PMID: 9205820 Free PMC article. Clinical Trial.

5

The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.

Snoeck E, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Van Belle H, Woestenborghs R, Crabbé R, Van Gool R, Dupont A, Heykants J. Snoeck E, et al. Among authors: ver donck k. Br J Clin Pharmacol. 1996 Nov;42(5):605-13. doi: 10.1111/j.1365-2125.1996.tb00116.x. Br J Clin Pharmacol. 1996. PMID: 8951192 Free article.

6

Role of nucleoside transport inhibition and endogenous adenosine in prevention of catecholamine induced death in rabbits.

Van Belle H, Ver Donck K, Verheyen W. Van Belle H, et al. Among authors: ver donck k. Cardiovasc Res. 1993 Jan;27(1):111-5. doi: 10.1093/cvr/27.1.111. Cardiovasc Res. 1993. PMID: 8458020

7

Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor.

Van Belle H, Verheyen W, Ver Donck K, Janssen PA, Robertson JI. Van Belle H, et al. Among authors: ver donck k. J Cardiovasc Pharmacol. 1992 Aug;20(2):173-8. doi: 10.1097/00005344-199208000-00001. J Cardiovasc Pharmacol. 1992. PMID: 1381007

8

Comparison of the existing nucleoside transport inhibitors: in vitro and in vivo data.

Van Belle H, Wynants J, Ver Donck K. Van Belle H, et al. Among authors: ver donck k. Adv Exp Med Biol. 1991;309A:419-22. doi: 10.1007/978-1-4899-2638-8_96. Adv Exp Med Biol. 1991. PMID: 1789258 No abstract available.

9

High-grade nucleoside transport inhibition stimulates ventilation in humans.

Rongen GA, Smits P, Bootsma G, Ver Donck K, de Vries A, Thien T. Rongen GA, et al. Among authors: ver donck k. J Clin Pharmacol. 1995 Apr;35(4):357-61. doi: 10.1002/j.1552-4604.1995.tb04073.x. J Clin Pharmacol. 1995. PMID: 7650223 Free article. Clinical Trial.

10

Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.

Rongen GA, Smits P, Ver Donck K, Willemsen JJ, De Abreu RA, Van Belle H, Thien T. Rongen GA, et al. Among authors: ver donck k. J Clin Invest. 1995 Feb;95(2):658-68. doi: 10.1172/JCI117711. J Clin Invest. 1995. PMID: 7860749 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results